Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ursodeoxycholic acid

Drug Profile

Ursodeoxycholic acid

Alternative Names: Actigall; Delursan; LJDCA; UDCA; Urso; Urso 500; Urso DS; Urso Forte; Ursobilane; Ursochol; Ursodesoxycholic acid; Ursodiol; Ursolite; Ursosan

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alfa Farmaceutici; sanofi-aventis
  • Developer Adare Pharmaceuticals; Allergan; Axcan Pharma; Estedi; Mitsubishi Tanabe Pharma Corporation; Novartis; Procter & Gamble Pharmaceuticals Spain; sanofi-aventis; Zambon Company SpA
  • Class Cholic acids; Gallstone therapies; Hepatoprotectants; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Cholesterol inhibitors; Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cholelithiasis; Liver disorders; Primary biliary cirrhosis; Primary sclerosing cholangitis
  • No development reported Colorectal cancer; Hypercholesterolaemia; Liver transplant rejection; Non-alcoholic steatohepatitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 Jun 2015 No recent reports on development identified - Phase-II for Non-alcoholic steatohepatitis in USA (PO)
  • 10 Jun 2015 No recent reports on development identified - Phase-II/III for Colorectal cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top